US Bancorp’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-8
| Closed | -$91 | – | 4164 |
|
|
2023
Q4 | $91 | Hold |
8
| – | – | ﹤0.01% | 3920 |
|
|
2023
Q3 | $32 | Sell |
8
-1
| -11% | -$7 | ﹤0.01% | 3957 |
|
|
2023
Q2 | $63 | Hold |
9
| – | – | ﹤0.01% | 3949 |
|
|
2023
Q1 | $66 | Hold |
9
| – | – | ﹤0.01% | 4050 |
|
|
2022
Q4 | $65 | Hold |
9
| – | – | ﹤0.01% | 4097 |
|
|
2022
Q3 | $0 | Hold |
9
| – | – | ﹤0.01% | 4270 |
|
|
2022
Q2 | $0 | Hold |
9
| – | – | ﹤0.01% | 4294 |
|
|
2022
Q1 | $0 | Hold |
9
| – | – | ﹤0.01% | 4258 |
|
|
2021
Q4 | $1K | Hold |
9
| – | – | ﹤0.01% | 4062 |
|
|
2021
Q3 | $1K | Sell |
9
-24
| -73% | -$2.41K | ﹤0.01% | 4043 |
|
|
2021
Q2 | $5K | Sell |
33
-18
| -35% | -$3.43K | ﹤0.01% | 3638 |
|
|
2021
Q1 | $11K | Sell |
51
-120
| -70% | -$24.1K | ﹤0.01% | 3263 |
|
|
2020
Q4 | $28K | Buy |
171
+51
| +43% | +$7.88K | ﹤0.01% | 2766 |
|
|
2020
Q3 | $20K | Buy |
120
+54
| +82% | +$7.79K | ﹤0.01% | 2822 |
|
|
2020
Q2 | $11K | Buy |
66
+6
| +10% | +$936 | ﹤0.01% | 3086 |
|
|
2020
Q1 | $7K | Buy |
60
+30
| +100% | +$4.22K | ﹤0.01% | 3159 |
|
|
2019
Q4 | $4K | Hold |
30
| – | – | ﹤0.01% | 3363 |
|
|
2019
Q3 | $4K | Buy |
+30
| New | +$4.22K | ﹤0.01% | 3309 |
|
US Bancorp's HARP Position: Q1 2024 in Review
US Bancorp sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q1 2024, closing a stake of 8 shares — an estimated $91 sold.
US Bancorp first reported a position in HARP in Q3 2019 and held it in 18 quarters. The position peaked at $28K in Q4 2020. 0 funds tracked by Wall St. Rank hold HARP as of Q1 2024.
- US Bancorp reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- US Bancorp sold 8 Harpoon Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $91.
- US Bancorp first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q3 2019 and held it in 18 quarters.
- US Bancorp's Harpoon Therapeutics, Inc. Common Stock position peaked at $28K in Q4 2020.
- 0 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q1 2024.
Based on US Bancorp's 13F filing for Q1 2024, filed 8 May 2024.